Fruquintinib + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Fruquintinib + Placebo
Fruquintinib + Placebo is a phase 3 stage product being developed by HUTCHMED for NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT02691299. Target conditions include NSCLC.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04322539 | Phase 3 | Completed |
| NCT02691299 | Phase 3 | Completed |
| NCT02314819 | Phase 3 | Completed |
| NCT02590965 | Phase 2 | Completed |
| NCT02196688 | Phase 2 | Completed |
Competing Products
20 competing products in NSCLC